Study of the Urinary Ratio of 6 beta-Hydroxycortisol/Cortisol as a Biomarker of CYP3A4 Activity in Egyptian Patients with Chronic Liver Diseases.
The urinary ratio of 6 beta-hydroxycortisol/cortisol (6 beta-OHC/C) as a biomarker of CYP3A4 metabolizing activity has been studied in Egyptian patients with chronic liver cirrhosis associated with previous hepatic Schistosomiasis infection to determine any possible alteration in enzyme activity. The ratio of 6-beta OHC/C was determined in morning urine samples collected from 8:00 a.m. to 12:00 p.m. in healthy adults (n = 36) and patients with liver cirrhosis (n = 57). The median age for control was 27 years (range: 18-50 years) and 50 years (range: 27-75 years) for patients. 6 beta-OHC was detected in urine by ELIZA kits (Stabiligen, France). Patients with liver cirrhosis were categorized according to Child Pugh Classification into Child B (n = 28) and Child C (n = 29) classes. Cholestasis was observed in 9/28 of Child B class and 8/29 of Child C class of patients. The control subjects showed gender-related difference in the urinary ratio of 6 beta-OHC/C. A significant reduction (P < 0.001) in 6 beta-OHC/C ratio was observed only in Child C patients in comparison with control subjects. Regression analysis showed a significant correlation (P < 0.05) between 6 beta-OHC/C ratio and serum albumin. The influence of cholestasis on the urinary ratio of 6-beta OHC/C was observed on cirrhotic patients of Child B class. In conclusion, patients with chronic liver cirrhosis might have a reduction of metabolizing activity of CYP3A4 enzymes which could be identified by measuring the urinary ratio of 6 beta-OHC/C. This reduction is more apparent in severe liver injury (Child C class). Therefore, it is important to understand the metabolic fate of drugs metabolized by 3A4 enzymes in patients with liver cirrhosis to avoid drug accumulation that might lead to development of drug toxicity.
Eldesoky
Ehab S
ES
Pharmacology Dept, Faculty of Medicine, Assiut University, Assiut, Egypt.
Kamel
Sherif I
SI
Farghaly
Ahlam M
AM
Bakheet
Madiha Y
MY
Hedaya
Mohsen A
MA
Siest
Jean-Pascal
JP
Annu Rev Pharmacol Toxicol. 1998;38:389-430
9597161
J Pharmacol Exp Ther. 1994 Oct;271(1):549-56
7965755
FASEB J. 1992 Jan 6;6(2):745-8
1537465
Br J Clin Pharmacol. 2003 Jan;55(1):86-93
12534644
Pharmacogenetics. 2000 Apr;10(3):187-216
10803676
J Pharmacol Exp Ther. 1997 Jul;282(1):391-6
9223579
Clin Endocrinol (Oxf). 2006 Jan;64(1):37-45
16402926
Drug Metab Dispos. 2002 Oct;30(10):1108-14
12228187
Pharmacogenetics. 2000 Jul;10(5):373-88
10898107
Ther Drug Monit. 2002 Dec;24(6):722-7
12451288
Drug Metab Rev. 1997 Feb-May;29(1-2):413-580
9187528
J Clin Pharmacol. 2004 Dec;44(12):1412-7
15545313
Can J Physiol Pharmacol. 2000 Nov;78(11):912-9
11100940
Hepatol Res. 2003 May;26(1):28-33
12787801
Br J Clin Pharmacol. 2002 Feb;53(2):203-6
11851646
Steroids. 2004 Jan;69(1):67-70
14715379
Liver. 2000 Jul;20(4):281-9
10959806
Pharmacogenetics. 2004 Oct;14(10):635-45
15454728
Clin Transplant. 2004 Apr;18(2):124-9
15016124
J Pharmacokinet Biopharm. 1996 Oct;24(5):475-90
9131486
Eur J Clin Pharmacol. 2003 Dec;59(10):713-33
14605790
Hepatology. 1995 Jan;21(1):120-8
7806144
Clin Pharmacol Ther. 1999 Sep;66(3):224-31
10511057
Pharmacogenetics. 2001 Dec;11(9):773-9
11740341
Clin Pharmacol Ther. 1993 Dec;54(6):621-9
8275617
J Pharmacol Exp Ther. 1994 Jul;270(1):414-23
8035341
Pharmacol Res. 2005 Jun;51(6):575-80
15829439
Clin Biochem. 1995 Feb;28(1):49-54
7720227
Drug Metab Pharmacokinet. 2002;17(6):522-31
15618707
Am J Physiol Gastrointest Liver Physiol. 2005 Jan;288(1):G74-84
15331348
J Clin Pharmacol. 2001 Jul;41(7):723-31
11452704
J Clin Oncol. 2002 Sep 1;20(17):3683-90
12202670
Nat Med. 2001 Mar;7(3):285-7
11231620
Nephron. 1976;16(1):31-41
1244564
J Hepatol. 1997 Feb;26(2):236-43
9059941
Clin Chim Acta. 1986 Jun 30;157(3):267-76
3731488
Clin Pharmacol Ther. 1992 Jan;51(1):18-23
1732074
Cancer. 1996 Apr 15;77(8):1427-33
8608525
Drug Metab Dispos. 2006 May;34(5):756-64
16455805
Toxicol Appl Pharmacol. 2004 Sep 15;199(3):193-209
15364537
Cancer Epidemiol Biomarkers Prev. 2001 Mar;10(3):237-42
11303593
Br J Clin Pharmacol. 2006 Feb;61(2):200-10
16433874
Mol Pharmacol. 2002 Jul;62(1):162-72
12065767
Clin Biochem. 2005 Jun;38(6):531-4
15885232
J Med Virol. 1995 Apr;45(4):423-8
7545213
Acta Physiol Hung. 2003;90(3):217-23
14594192
J Clin Pharmacol. 2002 Dec;42(12):1374-9
12463733
J Clin Pharmacol. 1999 Jun;39(6):578-82
10354961
Hepatology. 1994 Jun;19(6):1513-20
8188183
J Pharmacol Exp Ther. 1994 Oct;271(1):557-66
7965756
Clin Pharmacol Ther. 1992 Sep;52(3):265-73
1526083
Biochim Biophys Acta. 2005 Feb 21;1687(1-3):84-93
15708356
Drug Metab Dispos. 2003 Nov;31(11):1283-7
14570755
Hepatology. 1994 Apr;19(4):933-40
8138268